215 related articles for article (PubMed ID: 27589012)
21. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
Tandon RT; Jimenez-Cortez Y; Taub R; Borczuk AC
Arch Pathol Lab Med; 2018 Feb; 142(2):236-242. PubMed ID: 29048219
[TBL] [Abstract][Full Text] [Related]
23. Improving the Accuracy of Mesothelioma Diagnosis in China.
Guo Z; Carbone M; Zhang X; Su D; Sun W; Lou J; Gao Z; Shao D; Chen J; Zhang G; Hu J; Chen K; Wang F; Pass HI; Yu H; Napolitano A; Yang H; Mao W
J Thorac Oncol; 2017 Apr; 12(4):714-723. PubMed ID: 28007630
[TBL] [Abstract][Full Text] [Related]
24. Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma.
Ohta Y; Sasaki Y; Saito M; Kushima M; Takimoto M; Shiokawa A; Ota H
Int J Surg Pathol; 2013 Oct; 21(5):493-501. PubMed ID: 23775021
[TBL] [Abstract][Full Text] [Related]
25. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
26. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
[TBL] [Abstract][Full Text] [Related]
27. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.
Wu M; Wang B; Gil J; Sabo E; Miller L; Gan L; Burstein DE
Am J Clin Pathol; 2003 May; 119(5):696-702. PubMed ID: 12760288
[TBL] [Abstract][Full Text] [Related]
28. [Comparing the results of pathologic diagnosis of mesothelioma between Chinese and Japanese experts].
Lou J; Gao Z; Jiang Z; Chen J; Chen R; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2015 Jan; 33(1):33-6. PubMed ID: 25876971
[TBL] [Abstract][Full Text] [Related]
29. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Kushitani K; Kai Y; Suzuki R; Miyata Y; Okada M; Takeshima Y
Mod Pathol; 2018 May; 31(5):809-815. PubMed ID: 29327712
[TBL] [Abstract][Full Text] [Related]
30. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
Pu RT; Pang Y; Michael CW
Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
[TBL] [Abstract][Full Text] [Related]
31. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.
Li Q; Bavikatty N; Michael CW
Semin Diagn Pathol; 2006 Feb; 23(1):15-9. PubMed ID: 17044191
[TBL] [Abstract][Full Text] [Related]
32. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Takeshima Y
Mod Pathol; 2017 May; 30(5):672-681. PubMed ID: 28128276
[TBL] [Abstract][Full Text] [Related]
33. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
Kim MJ; Shin HC; Shin KC; Ro JY
Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
[TBL] [Abstract][Full Text] [Related]
34. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
Naso JR; Tsuji S; Churg A
Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
[TBL] [Abstract][Full Text] [Related]
35. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
36. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
37. Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
Marchevsky AM
Arch Pathol Lab Med; 2008 Mar; 132(3):397-401. PubMed ID: 18318582
[TBL] [Abstract][Full Text] [Related]
38. SOX6 is a Novel Immunohistochemical Marker for Differential Diagnosis of Epithelioid Mesothelioma From Lung Adenocarcinoma.
Kambara T; Amatya VJ; Kushitani K; Suzuki R; Fujii Y; Kai Y; Miyata Y; Okada M; Takeshima Y
Am J Surg Pathol; 2020 Sep; 44(9):1259-1265. PubMed ID: 32496433
[TBL] [Abstract][Full Text] [Related]
39. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
van Zyl A; Schubert PT; Koegelenberg CFN
Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
[TBL] [Abstract][Full Text] [Related]
40. Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.
Sejben A; Pancsa T; Tiszlavicz L; Furák J; Paróczai D; Zombori T
Thorac Cancer; 2023 Apr; 14(10):857-863. PubMed ID: 36808895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
